Selective estrogen receptor-β ligands
US7256201B2 · kind B2 · utility
12Cited by
0References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 7, 2001 |
| Grant date | Aug 14, 2007 |
| Priority date | — |
| Expiry date | Sep 1, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D409/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to novel compounds having the general formula: (I) and arc useful as selective ER-β ligands in the treatment or prophylaxis of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis cardiovascular disease, rheumatoid arthritis or prostate cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.